

Ruth Eichner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6431277/publications.pdf>

Version: 2024-02-01

7
papers

207
citations

2257263

3
h-index

1872312

6
g-index

7
all docs

7
docs citations

7
times ranked

476
citing authors

#	ARTICLE	IF	CITATIONS
1	MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 515-520.	2.5	5
2	The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. <i>Molecular Cell</i> , 2021, 81, 1170-1186.e10.	4.5	39
3	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	0.6	1
4	Cross Talk Networks of Mammalian Target of Rapamycin Signaling With the Ubiquitin Proteasome System and Their Clinical Implications in Multiple Myeloma. <i>International Review of Cell and Molecular Biology</i> , 2019, 343, 219-297.	1.6	16
5	MCT1 As Molecularly Validated Predictive Marker for Lenalidomide-Maintenance Therapy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 3187-3187.	0.6	1
6	The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism. <i>Blood</i> , 2019, 134, 314-314.	0.6	0
7	Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. <i>Nature Medicine</i> , 2016, 22, 735-743.	15.2	145